Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Angiosarcoma Clinical Trial

Official title:

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05799612
• Other study ID #: 2021-0018
• Secondary ID: NCI-2023-02650
• Status: Recruiting
• Phase: Phase 1
• Start date: March 22, 2024
• Est. completion date: December 31, 2029

Study information

• Verified date: March 2024
• Source: M.D. Anderson Cancer Center
• Contact: Vinod Ravi, MD
• Phone: (713) 792-1641
• Email: vravi[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma

Description:

Objectives: Primary objective: •To determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy. Secondary objective: • To assess the recurrence free survival and overall survival in treated patients in order to make initial assessment of activity of this therapeutic approach Exploratory Objectives: • To quantitate immune responses in patients who receive autologous DCs loaded with tumor lysate plus mRNA

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Patients with histologically confirmed cutaneous head & neck angiosarcoma deemed to be potentially resectable and who are deemed to be good candidates for postoperative therapy with radiation and study treatment.

2. Should be willing to undergo biopsy to provide fresh frozen tumor tissue for use in the creation of the vaccine.

3. 18 years of age or older and able to provide informed consent.

4. Adequate kidney, liver, bone marrow function, and immune function, as follows:

• Hemoglobin = 8.0 gm/dL
• Absolute neutrophil count (ANC) = 1,500 cells/mm3
• Lymphocytes = 500 cells/mm3
• Platelet count = 75,000 /mm3
• CD4+ T-cell counts = 200/mm3
• Glomerular filtration rate (GFR) > 60 mL/min/m2
• For males = (140 - age[years]) x (body weight [kg]) (72) x (serum creatinine [mg/dL]
• For females = 0.85 x male value
• Total bilirubin = 1.5 times upper limit of normal (ULN),
• Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) = 2.5 times the ULN
• TSH range between 0.4 - 4.0 mIU / L
• aPTT or INR = 1.5 × ULN unless subject is receiving anticoagulant therapy. If receiving anticoagulant therapy, patient is eligible as long as prothrombin time, international normalized ratio (INR), or activated partial thromboplastin time is within therapeutic range of intended use of anticoagulants

5. ECOG performance status = 2.

Exclusion criteria:

1. Locally advanced tumors deemed unresectable and/or metastatic tumors

2. Received live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine.

3. Uncontrolled HIV infection with CD4+ <200 c ells/µl or active HBC or HCV disease that requires antiviral therapy.

4. Need for concurrent therapy with corticosteroids or any systemic immunosuppressive agents during the vaccination phase of the study.

5. History of systemic autoimmune disease

6. Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline. Male or female patients of childbearing potential unwilling to use contraceptive precautions (refer Table 1) throughout the trial and 3 months following discontinuation of study treatment. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative serum pregnancy test prior to the first treatment.

7. Concurrent participation on another therapeutic clinical trial.

8. Patients unwilling or unable to comply with the protocol or provide informed consent.

Related Conditions & MeSH terms

• Angiosarcoma

Intervention

Drug:
• Paclitaxel
Given by IV (vein)

Biological:
• mRNA plus Lysate-loaded Dendritic Cell Vaccine
Given by IV (vein)

Drug:
• PEGYLATED-INTERFERON ALPHA-2A
Given by IV (vein)
• Filgrastim
Given by IV (vein)

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	Cancer Cures 4 Kids

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0		through study completion; an average of 1 year

External Links

•   M D Anderson Cancer Center